Please use this identifier to cite or link to this item:
http://hdl.handle.net/2445/183783
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Bosch Barrera, Joaquim | - |
dc.contributor.author | Roqué, Ariadna | - |
dc.contributor.author | Teixidor, Eduard | - |
dc.contributor.author | Carmona García, M. Carmen | - |
dc.contributor.author | Arbusà, Aina | - |
dc.contributor.author | Brunet, Joan | - |
dc.contributor.author | Martin Castillo, Begoña | - |
dc.contributor.author | Cuyàs, Elisabet | - |
dc.contributor.author | Verdura, Sara | - |
dc.contributor.author | Menendez, Javier A. | - |
dc.date.accessioned | 2022-03-04T12:13:46Z | - |
dc.date.available | 2022-03-04T12:13:46Z | - |
dc.date.issued | 2021-12-24 | - |
dc.identifier.uri | http://hdl.handle.net/2445/183783 | - |
dc.description.abstract | COVID-19 pathophysiology is caused by a cascade of respiratory and multiorgan failures arising, at least in part, from the SARS-CoV-2-driven dysregulation of the master transcriptional factor STAT3. Pharmacological correction of STAT3 over-stimulation, which is at the root of acute respiratory distress syndrome (ARDS) and coagulopathy/thrombosis events, should be considered for treatment of severe COVID-19. In this perspective, we first review the current body of knowledge on the role of STAT3 in the pathogenesis of severe COVID-19. We then exemplify the potential clinical value of treating COVID-19 disease with STAT3 inhibitors by presenting the outcomes of two hospitalized patients with active cancer and COVID-19 receiving oral Legalon(R)-a nutraceutical containing the naturally occurring STAT3 inhibitor silibinin. Both patients, which were recruited to the clinical trial SIL-COVID19 (EudraCT number: 2020-001794-77) had SARS-CoV-2 bilateral interstitial pneumonia and a high COVID-GRAM score, and showed systemic proinflammatory responses in terms of lymphocytopenia and hypoalbuminemia. Both patients were predicted to be at high risk of critical COVID-19 illness in terms of intensive care unit admission, invasive ventilation, or death. In addition to physician's choice of best available therapy or supportive care, patients received 1050 mg/day Legalon(R) for 10 days without side-effects. Silibinin-treated cancer/COVID-19+ patients required only minimal oxygen support (2-4 L/min) during the episode, exhibited a sharp decline of the STAT3-regulated C-reactive protein, and demonstrated complete resolution of the pulmonary lesions. These findings might inspire future research to advance our knowledge and improve silibinin-based clinical interventions aimed to target STAT3-driven COVID-19 pathophysiology. | - |
dc.format.extent | 15 p. | - |
dc.format.mimetype | application/pdf | - |
dc.language.iso | eng | - |
dc.publisher | MDPI AG | - |
dc.relation.isformatof | Reproducció del document publicat a: https://doi.org/10.3390/ph15010019 | - |
dc.relation.ispartof | Pharmaceuticals, 2021, vol. 15, num. 1, p. 19 | - |
dc.relation.uri | https://doi.org/10.3390/ph15010019 | - |
dc.rights | cc by (c) Bosch Barrera, Joaquim et al., 2021 | - |
dc.rights.uri | http://creativecommons.org/licenses/by/3.0/es/ | * |
dc.source | Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL)) | - |
dc.subject.classification | COVID-19 | - |
dc.subject.classification | Medicina clínica | - |
dc.subject.classification | Malalts de càncer | - |
dc.subject.other | COVID-19 | - |
dc.subject.other | Clinical medicine | - |
dc.subject.other | Cancer patients | - |
dc.title | Clinical Management of COVID-19 in Cancer Patients with the STAT3 Inhibitor Silibinin | - |
dc.type | info:eu-repo/semantics/article | - |
dc.type | info:eu-repo/semantics/publishedVersion | - |
dc.date.updated | 2022-03-03T12:43:38Z | - |
dc.rights.accessRights | info:eu-repo/semantics/openAccess | - |
dc.identifier.pmid | 35056076 | - |
Appears in Collections: | Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL)) |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
pharmaceuticals-15-00019.pdf | 2.88 MB | Adobe PDF | View/Open |
This item is licensed under a Creative Commons License